Hyposwiss Advisors’s iShares iBonds Dec 2032 Term Corporate ETF IBDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$212K Buy
8,425
+100
+1% +$2.52K 0.2% 60
2026
Q1
$210K Hold
8,325
0.21% 61
2025
Q4
$213K Buy
+8,325
New +$213K 0.21% 60

Other funds holding IBDX

Hyposwiss Advisors's IBDX Position: Q2 2026 in Review

Hyposwiss Advisors increased its iShares iBonds Dec 2032 Term Corporate ETF (IBDX) stake by 1.2% in Q2 2026, buying an estimated $2.52K and bringing the position to 8,425 shares worth $212K. The position accounts for 0.2% of the portfolio, ranked #60.

Hyposwiss Advisors first reported a position in IBDX in Q4 2025 and has held it in 3 quarters since. The position peaked at $213K in Q4 2025. 228 funds tracked by Wall St. Rank hold IBDX as of Q2 2026.

  • Hyposwiss Advisors held 8,425 shares of iShares iBonds Dec 2032 Term Corporate ETF worth $212K as of Q2 2026.
  • Hyposwiss Advisors bought 100 iShares iBonds Dec 2032 Term Corporate ETF shares in Q2 2026, an estimated $2.52K.
  • iShares iBonds Dec 2032 Term Corporate ETF made up 0.2% of Hyposwiss Advisors's portfolio in Q2 2026, its #60 holding.
  • Hyposwiss Advisors first reported a position in iShares iBonds Dec 2032 Term Corporate ETF in Q4 2025 and has held it in 3 quarters since.
  • Hyposwiss Advisors's iShares iBonds Dec 2032 Term Corporate ETF position peaked at $213K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iShares iBonds Dec 2032 Term Corporate ETF as of Q2 2026.

Based on Hyposwiss Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.